FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Italy Fines Apple €98.6 Million Over App Store Dominance 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
REHOVOT, Israel, Sept. 07, 2017 -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that Amir London, Chief Executive Officer, will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 3rd Annual Healthcare Conference.
| Cantor Fitzgerald Global Healthcare Conference | ||
| Date: | Monday, September 25 | |
| Time: | 3:00pm Eastern Time | |
| Location: | InterContinental New York Barclay Hotel, New York City, Grand Ballroom #2 | |
| Webcast: | http://wsw.com/webcast/cantor6/kmda/ | |
| Ladenburg Thalmann 3rd Annual Healthcare Conference | ||
| Date: | Tuesday, September 26 | |
| Time: | 8:30am Eastern Time | |
| Location: | Sofitel New York Hotel, Odeon Ballroom | |
About Kamada
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company’s flagship product is GLASSIA®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership with Baxalta (now part of Shire plc) and in other counties through local distributors. In addition to GLASSIA®, Kamada has a product line of seven other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency. In addition, Kamada's intravenous AAT is in development for other indications, such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada's rabies immune globulin (Human) product received FDA approval for Post-Exposure Prophylaxis against rabies infection in August 2017. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties.
CONTACTS: Gil Efron Deputy CEO & Chief Financial Officer [email protected] Bob Yedid LifeSci Advisors, LLC 646-597-6989 [email protected]
